Search

Your search keyword '"HemispheRx BioPharma Inc. -- Product development"' showing total 7 results
Start Over Descriptor "HemispheRx BioPharma Inc. -- Product development" Search Limiters Available in Library Collection
7 results on '"HemispheRx BioPharma Inc. -- Product development"'

1. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc

Subjects
United States. Food and Drug Administration, HemispheRx BioPharma Inc. -- Product development, Securities fraud, Biological products industry -- Product development, Class actions (Civil procedure), Health, Ampligen (Medication)
Abstract

By a News Reporter-Staff News Editor at Clinical Trials Week -- Shareholder rights attorneys at Robbins Arroyo LLP announce that purchasers of Hemispherx Biopharma, Inc. (NYSE: HEB) ('Hemispherx' or the [...]

Published
2013

2. Hemispherx Biopharma, Inc

Subjects
HemispheRx BioPharma Inc. -- Product development, Antiviral agents -- Evaluation -- Product development, Anti-HIV agents -- Evaluation, Pharmaceutical industry -- Product development, General interest, Health, Evaluation, Product development
Abstract

Phase 2 Most recent data of the Hemispherx Biopharma, Inc. (Philadelphia, PA) Phase 2b clinical trial, AMP 720, was reported. Using Strategic Treatment Interruption (STI), subjects' antiviral HAART regimens are [...]

Published
2003

3. Quest PharmaTech Announces Clinical Development Agreement with Hemispherx Biopharma Inc. to evaluate a combinatorial Immunotherapy Technology

Subjects
HemispheRx BioPharma Inc. -- Product development, Biological products industry -- Product development, Homeopathy -- Materia medica and therapeutics, Immunotherapy, Drugs -- Product development, Therapeutics -- Product development, Cancer -- Care and treatment, Health
Abstract

Quest PharmaTech Inc. (TSX-V: QPT) ('Quest' or the 'Company'), a pharmaceutical company developing and commercializing products for the treatment of cancer, announced a clinical development arrangement with U.S. based Hemispherx [...]

Published
2011

4. Hemispherx to expand CFS program

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Product development, Business, Pharmaceuticals and cosmetics industries, Retail industry, Ampligen (Medication) -- Product development
Abstract

Hemispherx Biopharma Inc. has received authorization from the FDA to more than double the number of patients undergoing treatment in its program for chronic fatigue syndrome. The action means that [...]

Published
1999

5. Hemispherx gears up for NDA with Ampligen data

Subjects
HemispheRx BioPharma Inc. -- Planning, HemispheRx BioPharma Inc. -- Product development, Pharmaceutical industry -- Planning, Pharmaceutical industry -- Product development, Company business planning, Biotechnology industry
Abstract

With hopes of soon filing a new drug application for Ampligen, Hemispherx Biopharma Inc. presented new Phase III data that support the drug's use in chronic fatigue syndrome. At the [...]

Published
2004

6. Laboratories Del Dr. Esteve SA, of Barcelona, Spain, received import authorization for Ampligen, which is partnered with Hemispherx Biopharma Inc., of Philadelphia, to conduct a clinical trial in patients coinfected with hepatitis C and HIV viruses

Subjects
HemispheRx BioPharma Inc. -- Product development, HIV (Viruses), Clinical trials, Hepatitis C, Comorbidity, Biotechnology industry, Business, Business, international
Abstract

* Laboratories Del Dr. Esteve SA, of Barcelona, Spain, received import authorization for Ampligen, which is partnered with Hemispherx Biopharma Inc., of Philadelphia, to conduct a clinical trial in patients [...]

Published
2004

7. Hemispherx's Ampligen hits endpoint in CFS

Subjects
HemispheRx BioPharma Inc. -- Product development, Chronic fatigue syndrome -- Care and treatment, Biotechnology industry -- Product development, Biotechnology industry
Abstract

Hemispherx Biopharma Inc. a-chieved its primary endpoint in a pivotal Phase III trial of Ampligen to treat chronic fatigue syndrome (CFS), giving the Philadelphia-based company the data it needs to [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results